Multiple first-in-human trials showed functional and biomarker improvements in early data reported at ASGCT's annual meeting.

The analysis by Ontada tracked testing rates within the US Oncology Network for PD-L1, FGFR2/3, and HER2 biomarkers over 10 ...

Moving forward, the biotech said it will focus its resources on developing treatments for genetic liver diseases and on its partnered programs.